5-Methyl-1,3,4-triphenylpyrazol | 7188-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Methyl-1,3,4-triphenylpyrazol
• 英文别名: 5-methyl-1,3,4-triphenyl-1H-pyrazole；5-methyl-1,3,4-triphenylpyrazole
• CAS: 7188-92-3
• 化学式: C₂₂H₁₈N₂
• 分子量: 310.398
• InChiKey: NFKMLMAIWDHMJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (E)-1-(1,2-diphenylbut-3-yn-1-yl)-2-phenyldiazene 在 盐酸 作用下， 以 乙醚 、 水 为溶剂， 反应 16.0h， 以13 mg的产率得到5-Methyl-1,3,4-triphenylpyrazol
  参考文献：
  名称：

  钌和铜催化炔丙醇衍生物与腙的炔丙基取代反应

  摘要：

  路径切换：通过使用 N-单取代腙作为环境亲核试剂，实现了钌和铜催化炔丙醇衍生物的炔丙基取代反应，其亲核性通过两种不同的催化体系在碳和氮中心的亲核之间切换，提供炔丙醇分别为烷基化产物和炔丙基胺化产物。

  DOI：

  10.1002/chem.202103287

文献信息

• Aryldiazonium Salts Serve as a Dual Synthon: Construction of Fully Substituted Pyrazoles via Rongalite-Mediated Three-Component Radical Annulation Reaction
  作者：Miao Wang、Bo-Cheng Tang、Jia-Chen Xiang、Xiang-Long Chen、Jin-Tian Ma、Yan-Dong Wu、An-Xin Wu

  DOI：10.1021/acs.orglett.9b03212

  日期：2019.11.15

  efficient rongalite-mediated three-component radical annulation reaction to furnish fully substituted pyrazoles from aryldiazonium salts and α,β-unsaturated aldehydes or ketones under metal- and oxidant-free conditions at room temperature has been developed. In this transformation, aryldiazonium salts served as the precursor of both the aryl and aryl hydrazine units. Mechanistic investigations indicated

  在室温下，在无金属和无氧化剂的条件下，已经开发出了一种高效的由锌铁矿介导的三组分自由基环化反应，可以从芳基重氮盐和α，β-不饱和醛或酮提供完全取代的吡唑。在该转化中，芳基重氮盐用作芳基和芳基肼单元的前体。机理研究表明，在反应过程中，白云母可以同时起自由基引发剂和还原剂的作用。
• Multicomponent Pyrazole Synthesis from Alkynes, Nitriles, and Titanium Imido Complexes via Oxidatively Induced N–N Bond Coupling
  作者：Adam J. Pearce、Robin P. Harkins、Benjamin R. Reiner、Alexander C. Wotal、Rachel J. Dunscomb、Ian A. Tonks

  DOI：10.1021/jacs.9b13173

  日期：2020.3.4

  and pharmaceuticals. Pyrazole synthesis often requires hydrazine or related reagents where an intact N-N bond is conservatively installed into a pyrazole precursor fragment. Herein, we report the multicomponent oxidative coupling of alkynes, nitriles, and Ti imidos for the syn-thesis of multisubstituted pyrazoles. This modular method avoids potentially hazardous reagents like hydrazine, instead forming

  吡唑是一类重要的杂环，广泛存在于各种生物活性化合物和药物中。吡唑合成通常需要肼或相关试剂，其中完整的 NN 键保守地安装到吡唑前体片段中。在此，我们报告了炔烃、腈和 Ti 亚氨基的多组分氧化偶联，用于合成多取代吡唑。这种模块化方法避免了潜在危险的试剂，如肼，而是在最后一步通过 Ti 上的氧化诱导耦合形成 NN 键。这种转变的机理已经通过关键的二氮杂钛基环己二烯中间体的化学计量反应进行了深入研究，该中间体可以通过 Ti 亚氨基与腈和炔烃的多组分偶联、2-亚氨基-2H-氮丙啶的开环、或通过 4-氮杂二烯-1-胺衍生物的直接金属化。该反应的关键转变是 Ti 上的 2 电子氧化诱导的 NN 耦合。这是金属中心上正式 NN 耦合的罕见例子，它可能通过类似于纳扎罗夫环化的电循环机制发生。方便的是，这些 2-电子氧化的二氮杂钛基环己二烯中间体可以通过 1-电子氧化物质的歧化获得，这允许利用弱氧化剂，如 TEMPO。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093708A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型的亚硝基化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，以及包含至少一种亚硝基化NSAID的新型组合物，可选地包含至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性松弛因子水平或是一氧化氮合酶底物的化合物，以及/或至少一种治疗剂。该发明还提供包含至少一种亚硝基化NSAID和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供包含至少一种亚硝基化NSAID，可选地包括至少一种一氧化氮供体和/或至少一种治疗剂的新型套件。该发明还提供用于治疗炎症、疼痛和发热的方法；用于治疗胃肠道疾病的方法；用于促进伤口愈合的方法；用于治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；用于治疗炎症性疾病状态和/或疾病的方法；以及用于治疗和/或预防眼科疾病和/或疾病的方法。
• MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC
  申请人：ANDERSSON Johan

  公开号：US20090170934A1

  公开（公告）日：2009-07-02

  The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds. The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl 2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.

  本发明涉及一种使用磺化中间体制备NO供体化合物的新工艺。该发明涉及其中制备的适用于NO供体化合物大规模生产的新中间体。本发明还涉及使用新中间体制造药用活性NO供体化合物。此外，本发明还涉及NO供体NSAIDs的实质晶体形式，特别是2-[2-(硝氧基)乙氧基]乙基2-[(2,6-二氯苯基)氨基]苯基}乙酸酯的制备，以及含有该晶体形式的制药配方和在制备药物时使用该晶体形式的用途。
• Compound, preparing method therefor, and organic light emitting element comprising same
  申请人：DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US11345688B2

  公开（公告）日：2022-05-31

  The compound is represented by Formula 1. In Formula 1, X is O or S, and R1 and R2 are independently selected from the group consisting of aryl, heteroaryl and —P(O)—R3R4, where the aryl, heteroaryl and —P(O)—R3R4 are substituted or unsubstituted with 1 to 4 substituents selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, aryl and heteroaryl. The “aryl” means a group consisting of 6 to 10 cyclic rings, and the “heteroaryl” means a group consisting of 5 to 14 cyclic rings having 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen (including quaternary nitrogen). R3 and R4 are independently selected from aryl or heteroaryl.

  该化合物由式 1 表示。在式 1 中，X 是 O 或 S，R1 和 R2 独立地选自由芳基、杂芳基和-P(O)-R3R4 组成的组，其中芳基、杂芳基和-P(O)-R3R4 被选自由 (C1-C4)烷基、(C1-C4)烷氧基、芳基和杂芳基组成的组的 1 至 4 个取代基取代或未被取代。芳基 "指由 6 至 10 个环组成的基团，"杂芳基 "指由 5 至 14 个环组成的基团，这些环具有 1 至 4 个选自氧、硫和氮（包括季氮）的杂原子。R3 和 R4 独立选自芳基或杂芳基。